JP2006502187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502187A5 JP2006502187A5 JP2004537943A JP2004537943A JP2006502187A5 JP 2006502187 A5 JP2006502187 A5 JP 2006502187A5 JP 2004537943 A JP2004537943 A JP 2004537943A JP 2004537943 A JP2004537943 A JP 2004537943A JP 2006502187 A5 JP2006502187 A5 JP 2006502187A5
- Authority
- JP
- Japan
- Prior art keywords
- pat
- combination
- thiazolidinedione
- teaches
- antihyperglycemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- -1 thiazolidinedione compound Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41218102P | 2002-09-20 | 2002-09-20 | |
| US41218002P | 2002-09-20 | 2002-09-20 | |
| US60/412,181 | 2002-09-20 | ||
| US60/412,180 | 2002-09-20 | ||
| PCT/US2003/029292 WO2004026241A2 (en) | 2002-09-20 | 2003-09-19 | Multistage formulation containing a biguanide and thiazolidindione derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006502187A JP2006502187A (ja) | 2006-01-19 |
| JP2006502187A5 true JP2006502187A5 (enExample) | 2006-06-15 |
| JP4694841B2 JP4694841B2 (ja) | 2011-06-08 |
Family
ID=32033587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004537943A Expired - Fee Related JP4694841B2 (ja) | 2002-09-20 | 2003-09-19 | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2604266A1 (enExample) |
| JP (1) | JP4694841B2 (enExample) |
| KR (4) | KR101363679B1 (enExample) |
| CN (2) | CN100544717C (enExample) |
| AU (1) | AU2003272504A1 (enExample) |
| CA (1) | CA2499597C (enExample) |
| ES (1) | ES2529180T3 (enExample) |
| WO (1) | WO2004026241A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8323692B2 (en) * | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| PL377403A1 (pl) * | 2003-01-29 | 2006-02-06 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania preparatu powlekanego |
| UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
| EP1962827A4 (en) * | 2005-12-16 | 2011-02-16 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN |
| US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
| CA2653786C (en) | 2006-05-23 | 2014-09-23 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| WO2011083998A2 (ko) * | 2010-01-06 | 2011-07-14 | 한올바이오파마주식회사 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| CA2802335A1 (en) * | 2010-06-22 | 2011-12-29 | Twi Pharmaceuticals, Inc. | Controlled release compositions with reduced food effect |
| WO2012028934A1 (en) | 2010-09-01 | 2012-03-08 | Lupin Limited | Pharmaceutical composition comprising metformin and pioglitazone |
| CN102008472B (zh) * | 2010-10-18 | 2012-08-22 | 中国科学院上海药物研究所 | 一种复方盐酸吡格列酮/盐酸二甲双胍双层渗透泵控释制剂及其制备方法 |
| CN101984974B (zh) * | 2010-11-15 | 2013-04-17 | 山东新华制药股份有限公司 | 一种用于治疗2型糖尿病的药物组合物的制备方法 |
| CN102727459A (zh) * | 2011-04-15 | 2012-10-17 | 江苏豪森医药集团有限公司 | 一种具有第一和第二活性药物的制剂 |
| MX2014004679A (es) | 2011-10-21 | 2014-08-01 | Takeda Pharmaceutical | Preparacion de liberacion sostenida. |
| AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| CN102920704A (zh) * | 2012-11-05 | 2013-02-13 | 上海现代药物制剂工程研究中心有限公司 | 含有双胍和噻唑烷二酮衍生物的药物制剂 |
| WO2014184742A1 (en) | 2013-05-13 | 2014-11-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
| KR102061390B1 (ko) | 2014-04-17 | 2019-12-31 | 이뮤노메트테라퓨틱스 인코포레이티드 | 구아니딘 화합물 및 그의 용도 |
| EP3025707A1 (en) * | 2014-11-27 | 2016-06-01 | Arven Ilac Sanayi Ve Ticaret A.S. | A multilayer tablet comprising metformin and pioglitazone |
| CN104473894A (zh) * | 2014-12-18 | 2015-04-01 | 浙江华海药业股份有限公司 | 一种盐酸吡格列酮载药包衣制剂及其制备方法 |
| CN106137999A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种复方吡格列酮二甲双胍缓释片及其制备方法 |
| KR101750690B1 (ko) * | 2015-10-28 | 2017-06-27 | 주식회사 종근당 | 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물 |
| CN108478537A (zh) * | 2018-05-03 | 2018-09-04 | 南京易亨制药有限公司 | 一种含普瑞巴林的单室渗透泵控释片剂 |
| PH12022552501A1 (en) * | 2020-05-29 | 2024-01-22 | Korea United Pharm Inc | Sustained-release metformin coated tablet having controlled release by osmotic pressure |
| US11684596B2 (en) * | 2020-09-22 | 2023-06-27 | Elite Pharmaceuticals Solution Inc. | Antidiabetic pharmaceutical compositions and preparation method thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| FR2243684B1 (enExample) | 1973-09-19 | 1977-01-28 | Semb | |
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4522625A (en) | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4587117A (en) | 1983-06-06 | 1986-05-06 | Alza Corporation | Medical device for delivering drug to pH environments greater than 3.5 |
| US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| US4851229A (en) | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US4892739A (en) | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
| US5071607A (en) | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
| US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
| US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
| DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| ID23372A (id) * | 1997-06-18 | 2000-04-20 | Smithkline Beecham Plc | Pengobatan diabetes dengan tiazolidindion dan metformin |
| GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6290699B1 (en) | 1999-07-07 | 2001-09-18 | Uab Research Foundation | Ablation tool for forming lesions in body tissue |
| AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
| AU1403501A (en) * | 1999-11-16 | 2001-05-30 | Smithkline Beecham Plc | Novel composition and use |
| WO2001047498A2 (en) * | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form comprising sertraline |
| SE0001151D0 (sv) * | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US6451342B2 (en) | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6780432B1 (en) * | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
| DE10025946A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
| US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| US20030224046A1 (en) * | 2002-06-03 | 2003-12-04 | Vinay Rao | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent |
-
2003
- 2003-09-19 JP JP2004537943A patent/JP4694841B2/ja not_active Expired - Fee Related
- 2003-09-19 AU AU2003272504A patent/AU2003272504A1/en not_active Abandoned
- 2003-09-19 EP EP13001210.7A patent/EP2604266A1/en not_active Withdrawn
- 2003-09-19 KR KR1020137005362A patent/KR101363679B1/ko not_active Expired - Fee Related
- 2003-09-19 CN CNB038223627A patent/CN100544717C/zh not_active Expired - Fee Related
- 2003-09-19 WO PCT/US2003/029292 patent/WO2004026241A2/en not_active Ceased
- 2003-09-19 KR KR1020127002220A patent/KR20120034211A/ko not_active Ceased
- 2003-09-19 KR KR1020107027556A patent/KR20100137023A/ko not_active Ceased
- 2003-09-19 KR KR1020057004787A patent/KR20050053677A/ko not_active Ceased
- 2003-09-19 CN CN2009101611482A patent/CN101623274B/zh not_active Expired - Fee Related
- 2003-09-19 EP EP03754689.2A patent/EP1539144B1/en not_active Expired - Lifetime
- 2003-09-19 CA CA2499597A patent/CA2499597C/en not_active Expired - Fee Related
- 2003-09-19 ES ES03754689.2T patent/ES2529180T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502187A5 (enExample) | ||
| AU2011202162B2 (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| RU2007129155A (ru) | Комплексная лекарственная форма с контролируемым высвобождением для перорального введения средства против диабета и способ ее получения | |
| CY1107966T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii | |
| KR20130137624A (ko) | 수용성 항산화제를 사용한 약물 제제 | |
| JP2013209426A (ja) | ビグアニドおよびチアゾリジンジオン誘導体を含有する新規な医薬品製剤 | |
| JP2009501178A5 (enExample) | ||
| CA2499597A1 (en) | Multistage formulation containing a biguanide and thiazolidindione derivatives | |
| HUP0202797A2 (hu) | Javított stabilitású készítmények | |
| RU2009110452A (ru) | Галеновые составы алискирена | |
| JP2006516141A5 (enExample) | ||
| US8084058B2 (en) | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| JP2001039976A5 (enExample) | ||
| JP2004536841A (ja) | コア製剤 | |
| JP2004536843A (ja) | ピオグリタゾンおよびビグアナイドを含むコア製剤 | |
| JPH09118624A5 (enExample) | ||
| CN105663130B (zh) | 一种具有第一和第二活性药物的制剂 | |
| JP4681843B2 (ja) | 固形医薬製剤 | |
| CA2532714A1 (en) | Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide | |
| TWI361070B (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| TH72850A (th) | สารผสมชนิดใหม่ | |
| JP2004536842A (ja) | トログリタゾンおよびビグアナイドを含むコア製剤 | |
| TH49271A (th) | อนุพันธ์ไทอะโซลิดีนไดโอนในฐานะสารต้านเบาหวาน | |
| HK1114337B (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| OA16217A (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative. |